Organometallic Ligands

Ro 31-8220 mesylate is a synthetic compound, which is a potent, selective inhibitor predominantly sourced from rational drug design techniques targeting the phosphodiesterase enzyme family. With its mode of action centered around the inhibition of protein kinase C (PKC) and other related kinases, Ro 31-8220 mesylate disrupts downstream signaling pathways, impacting cellular processes such as proliferation, differentiation, and apoptosis. This compound is used extensively in research settings to study signal transduction pathways and the role of kinases in various cellular functions. Its ability to selectively inhibit PKC makes it valuable for investigating the mechanisms underlying diseases where PKC is implicated, such as cancer, cardiovascular diseases, and neurological disorders. Additionally, Ro 31-8220 mesylate serves as a tool in pharmacological research to explore potential therapeutic targets and elucidate complex biochemical interactions within cells. The compound’s specificity and potency underscore its utility in advancing scientific understanding of kinase-related processes.

(-)-Nyasol is a naturally occurring lignan, which is a type of phytoestrogen found in certain plant species. It is primarily sourced from the roots of Anemarrhena asphodeloides, a herb widely used in traditional medicine. The compound exhibits its effects through modulation of estrogen receptors, demonstrating selective binding affinity that influences various estrogen-mediated pathways. The anti-inflammatory and anticancer potential of (-)-Nyasol is of particular interest. It exhibits a unique mode of action by modulating intracellular signaling pathways, including NF-kB and MAPK, which play pivotal roles in inflammatory responses and cancer cell proliferation. Additionally, its capacity to induce apoptosis and inhibit angiogenesis makes it a promising candidate for therapeutic research. Applications of (-)-Nyasol extend beyond its pharmacological potential. It is studied for its antioxidative properties and its role in mitigating oxidative stress, which is implicated in numerous diseases. Researchers continue to explore its full spectrum of biological activities, seeking to harness its natural properties for pharmaceutical development and understand its interactions at the molecular level.

SLF-100 is an enzymatic solution, which is derived from a consortium of beneficial microorganisms. This product functions by breaking down organic matter and releasing bound nutrients within the soil, thus enhancing nutrient availability and promoting plant health. The action of SLF-100 is mediated primarily by its enzymatic components, which include cellulase, amylase, and protease, among others. These enzymes work synergistically to degrade complex organic compounds, facilitating the release of macro and micronutrients. SLF-100 has applications in agricultural and horticultural settings, where it is utilized to improve soil fertility and boost plant growth. Its ability to enhance nutrient uptake makes it particularly useful for crops in nutrient-deficient soils or in conjunction with organic farming practices. In addition, SLF-100 can aid in the decomposition of organic amendments, thereby accelerating their benefits and contributing to sustainable soil management practices. Researchers and practitioners will find its mode of action relevant for both practical applications in the field and as a subject for further studies on enzyme-based soil amendments.

Laniquidar is a pharmacological agent classified as a third-generation multidrug resistance (MDR) modulator. It is derived from a class of compounds specifically designed to overcome MDR in cancer by targeting P-glycoprotein, a well-known efflux transporter protein. Laniquidar functions by inhibiting the action of P-glycoprotein, which is often overexpressed in various cancer cells and facilitates the efflux of chemotherapeutic drugs, thereby reducing their intracellular concentrations and effectiveness. The principal application of Laniquidar is in oncology, where it is explored as an adjuvant to conventional chemotherapeutic treatments. By sensitizing cancer cells to these treatments through the inhibition of drug efflux, it holds potential to enhance the efficacy of existing cancer therapies, especially in cases where tumors have developed resistance. While it is primarily under investigation for its potential in enhancing drug uptake in resistant cancer types, further studies continue to explore its broader applications and possible integration into cancer treatment regimens.

Pioglitazone is a thiazolidinedione drug that is used in combination with diet change and exercise to treat glycemic levels in patients with type 2 diabetes mellitus. This drug is an agonist of peroxisome proliferator-activated receptor-gamma and increases glucose uptake. In animal studies, Pioglitazone has shown to have anti-inflammatory properties.  Pioglitazone HCl is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

DH 97 is a highly specialized catalytic agent, which is a product derived from advanced bioorganic synthesis techniques with sophisticated molecular engineering. This catalytic agent is designed to facilitate specific chemical reactions by lowering the activation energy, thus enhancing efficiency and selectivity. The source of DH 97 involves the integration of synthetic organic compounds and biologically active materials, allowing for unique properties not found in traditional catalysts. The mode of action of DH 97 involves precise configurational interaction with substrate molecules, orchestrating the alignment and orientation necessary for effective transition state stabilization. This leads to enhanced reaction rates and increased yield of desired products while minimizing side reactions and byproducts. In practical applications, DH 97 is employed across various fields including pharmaceuticals, where it aids in the synthesis of complex molecules with high purity. It is also utilized in the field of materials science for the development of novel polymers and nanomaterials, where precise reaction control is paramount. Scientists appreciate its role in both academic research settings and industrial processes, where efficiency and specificity are critical for success.

(2R)-N-[4-[2-[(4-Morpholin-4-ylphenyl)amino]pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide is a small molecule inhibitor, which is synthetically derived and designed to interfere with specific protein kinase pathways that are crucial for cancer cell proliferation. The compound exerts its effect by targeting and inhibiting the activity of a distinct set of kinases, thereby disrupting downstream signaling pathways essential for tumor growth and survival. Its detailed mechanism of action involves competitive inhibition at the ATP-binding site of target kinases, effectively preventing substrate phosphorylation and subsequent signal transduction. This inhibition impedes cell cycle progression and induces apoptosis in cancerous cells, making it a compelling candidate in targeted cancer therapy. The applications of this molecule are primarily focused on oncological research, particularly in the development of targeted therapies aimed at tumors that exhibit overexpression or hyperactivation of specific kinases. Its comprehensive analysis in both in vitro and in vivo studies helps provide insights into the molecular basis of its action and assists in the design of combination therapies to improve clinical outcomes in oncology.

Amelubant is a synthetic compound designed for use in detailed biochemical research and therapeutic investigations. As a product derived from innovative chemical synthesis techniques, Amelubant is engineered to interact with particular biological pathways, predominantly in the field of inflammatory response modulation. Its mode of action involves specific binding to target receptors, influencing downstream signaling cascades. This compound is primarily utilized in experimental settings to elucidate intricacies of receptor-ligand interactions and is investigated for potential applications in managing inflammatory conditions. Researchers employ Amelubant to explore its efficacy in cellular and animal models to better understand its pharmacokinetic and pharmacodynamic properties. Its role in modulating specific biochemical pathways makes it indispensable in studies focusing on inflammation and immune response.

P-((4-((1-Oxotetradecyl)amino)phenyl)methyl)-phosphonic acid is a synthetic compound, which is a specialized reagent used primarily in chemical research. It is derived from the modification of phosphonic acid with an aryl amide and a long-chain fatty acid substituent on the phenyl group. This structural configuration imparts the compound with unique physicochemical properties that make it suitable for various scientific studies. The mode of action involves its interaction with specific biochemical pathways as it can mimic certain biomolecular interactions due to its amphiphilic nature. This results in its utility for probing phosphonate-related biological mechanisms and potential pharmaceutical development processes. In terms of applications, p-((4-((1-Oxotetradecyl)amino)phenyl)methyl)-phosphonic acid may be used in the synthesis of novel compounds, molecular biology experiments, and as a tool for investigating enzyme inhibition. Its use is critical in the development of new inhibitors or activators that target enzyme pathways, offering insights into therapeutic targets and mechanism elucidation in complex biological systems.

Dasatinib is a potent inhibitor of tyrosine kinases and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancer. It also inhibits many SRC- family kinases. Dasatinib has been shown to inhibit the proliferation of cancer cells, leading to cell lysis. Additionally, it has anti-angiogenic effects in vivo, inhibiting the development of new blood vessels in solid tumours. Dasatinib monohydrate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

3-Hydroxy-5-{[(naphthalen-2-yl)carbamoyl]amino}benzoic acid is a synthetic compound characterized by its complex molecular structure incorporating naphthalene and benzoic acid moieties. As a derivative of benzoic acid, it is typically synthesized through a series of chemical reactions designed to introduce the 3-hydroxy and carbamoyl functional groups, creating a compound with potentially unique bioactive properties. The mode of action of this compound is based on its ability to interact with specific biological targets, potentially influencing enzyme activity or receptor binding in a manner that is still the subject of ongoing research. This interaction can modulate biological pathways, potentially leading to therapeutic effects, although precise mechanisms may vary depending on the context. The principal interest in 3-Hydroxy-5-{[(naphthalen-2-yl)carbamoyl]amino}benzoic acid lies in its potential applications within pharmaceutical research, particularly in the development of novel therapeutics. Its diverse range of possible interactions makes it a candidate for further study in fields such as oncology, neurology, or immunology, where modulation of complex biological systems is desired. More detailed studies are necessary to fully understand its pharmacodynamics and pharmacokinetics to evaluate its suitability for clinical applications.

CXCR2-IN-1 is an inhibitor targeting the chemokine receptor CXCR2, which is synthesized through chemical methods. Its mode of action specifically involves the antagonism of the CXCR2 receptor, leading to the modulation of neutrophil recruitment and migration. This receptor is known for playing a pivotal role in inflammatory response pathways, making CXCR2-IN-1 a significant tool in experimental settings where modulation of this pathway is needed. The applications of CXCR2-IN-1 are primarily centered around inflammation and immune response research. By blocking the CXCR2 receptor, researchers can explore the impacts on cellular signaling pathways, particularly focusing on inflammatory diseases and conditions associated with abnormal chemotaxis. This compound is thus instrumental in both contributing to the understanding of complex biological processes and in potentially identifying novel therapeutic targets.

Prodrug of dihydroartemisin (DHA); antimalarial

Neratinib is a protein kinase inhibitor that is used in the treatment of breast cancer. This drug binds to and inhibits EGFR, HER2 and HER4. As a result of this, it prevents autophosphorylation of tyrosine residues and reduces oncogenic signalling. Neratinib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Ractopamine hydrochloride is a beta-agonist that stimulates the release of fatty acids from adipose tissue, increasing food intake and weight gain in pigs. It has been shown to have significant interactions with other drugs used for bowel disease, as well as with sodium carbonate, which can be used for control analysis. Ractopamine hydrochloride is an effective drug to stimulate the release of estradiol benzoate in rats during pregnancy. The matrix effect observed when analyzing samples containing ractopamine hydrochloride may be due to its ability to bind to serum proteins or lipids. This drug has been shown to have molecular docking properties that are similar to those found in other molecules.

6-(2,4-Difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one is a synthetic organic compound, specifically a pyrido[2,3-d]pyrimidine derivative. It is designed through organic synthesis processes that involve strategic modifications to achieve specific chemical characteristics. The compound acts primarily as an inhibitor within various biochemical pathways, targeting specific molecular interactions involved in pathological conditions. This compound finds applications in therapeutic research, particularly as a potential candidate for pharmacological intervention in diseases where modulation of its target pathways is advantageous. Researchers often explore its efficacy and specificity in preclinical models, aiming to elucidate its role in disease amelioration. The versatility of this compound within drug discovery exemplifies the intersection of chemical innovation and biological application, offering potential insights into treatments for various disorders. As research progresses, in-depth studies continue to uncover the potential mechanisms and therapeutic indices of this sophisticated chemical entity.

A selective inhibitor of glial glycine transporter type 1 (GlyT-1b). It has no considerable affinity for noradrenaline, dopamine, serotonin and GABA receptors. Increases amplitude of electronically evoked NMDA receptor-mediated glutamatergic excitatory postsynaptic current (eEPSCs). This raises glycine levels in spinal cord slides and extends the duration of current at glycinergic synapses.

Activator of SIRT1 deacetylase

BIA 10-2474 is an investigational pharmaceutical compound that functions as a fatty acid amide hydrolase (FAAH) inhibitor. This compound is derived from synthetic sources and works by inhibiting the FAAH enzyme, which is responsible for the degradation of endocannabinoids such as anandamide in the central nervous system. By inhibiting FAAH, BIA 10-2474 increases the levels of endocannabinoids, potentially impacting pain, mood, and neuroinflammation pathways. The primary research interest in BIA 10-2474 lies in its potential to treat neurological and psychiatric disorders through the modulation of the endocannabinoid system. Studies have been directed towards understanding its effects on chronic pain, anxiety, and neurodegenerative diseases. However, the clinical development of BIA 10-2474 faced significant setbacks due to severe adverse reactions observed in a Phase I clinical trial, highlighting the importance of careful evaluation of dosage and safety parameters. This compound has provided valuable insights into the pharmacological manipulation of the endocannabinoid system despite its challenges in clinical translation.

Furosemide is a potent loop diuretic that is used in the treatment of hypertension, liver cirrhosis, renal disease and heart failure. This drug acts on the kidney to increase water loss from the body. It inhibits electrolyte reabsorption. Furosemide also exerts vasodilatory effects. Furosemide is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.